Kidney Cancer | Tumor

CURE’s kidney cancer page is an extensive resource of cancer information featuring the latest kidney cancer news, expert oncologist insights on the latest cancer treatments, oncology research, advocacy efforts, and medical data on kidney cancer.

Data Sharing, Vigilance Pivotal in Maintaining Patient Safety While Treating Cancer Amid the COVID-19 Pandemic

September 2nd 2020

As the COVID-19 pandemic continues to impact the care of patients with metastatic renal cell carcinoma and other cancers, health care professionals are working together to stay vigilant and make the best treatment decisions for their patients by pooling their data with tools like the COVID-19 and Cancer Consortium, says Dr. Toni K. Choueiri.

Age and Gender Could Factor into Advanced Renal Cell Carcinoma Outcomes

September 1st 2020

Many factors impact outcomes in patients with advanced renal cell carcinoma, but recent findings suggest a patient’s age and gender are perhaps more important than previously realized.

FDA Approves First Comprehensive Genomic Profiling Liquid Biopsy Test for All Solid Cancers

August 10th 2020

The liquid biopsy test was also approved as a companion diagnostic test to uncover EGFR mutations in patients with NSCLC who could benefit from treatment with Tagrisso.

An Expert Looks to the Future of Metastatic Kidney Cancer Treatment

August 10th 2020

Dr. Toni K. Choueiri discusses what therapies are currently available for patients with metastatic renal cell carcinoma, as well as what new treatments could be on the horizon.

FDA Grants Breakthrough Therapy Designation to Novel Therapy for von Hippel-Lindau Disease-Associated RCC

August 7th 2020

The FDA based its decision on data from a phase 2 trial which showed that MK-6482 induced clinical responses among patients with von Hippel-Lindau disease-associated kidney cancer.

Opdivo-Yervoy Combination Shows Promise in Certain Patients with Previously Treated RCC

August 6th 2020

While the combination of Opdivo and Yervoy is one of several treatment options for patients with metastatic renal cell carcinoma, many patients will likely progress after initial treatment. However, new research shows that when used after immune checkpoint inhibition, the combination shows promise.

Combination of Avastin and Tarceva 'Should Be Considered Preferred Option' in Kidney Cancer Subtype

July 10th 2020

Data from a phase 2 study presented during the 2020 ASCO Virtual Scientific Program demonstrated that Avastin (bevacizumab) in combination with Tarceva (erlotinib) was well tolerated and produced encouraging clinical outcomes in patients with advanced hereditary leiomyomatosis and renal cell carcinoma or sporadic papillary renal cell carcinoma.

Experimental Therapy Demonstrates 'Encouraging Efficacy and Improved Safety' Over Standard-of-Care Treatment in Kidney Cancer Subset

July 10th 2020

Data from a phase 3 study presented at the 2020 ASCO Virtual Scientific Program showed that treatment with savolitinib demonstrated encouraging efficacy and an improved safety over standard-of-care Sutent (sunitinib) in patients with MET-driven papillary renal cell carcinoma.

The Latest News and Updates in Kidney Cancer

July 8th 2020

A roundup of the latest news and updates for patients with Renal Cell Carcinoma from CURE®.

More Options in Renal Cell Carcinoma Treatment Means Greater Hope For Patients

June 22nd 2020

A variety of novel treatments, including immunotherapies, extend life for patients with advanced kidney cancer.

Navigating Kidney Cancer Treatment During COVID-19

June 8th 2020

Getting kidney cancer treatment during the COVID-19 pandemic.

What Comes Next For Patients With Kidney Cancer

June 8th 2020

Kidney cancer positives that might come from this pandemic.

Kidney Cancer's Affect On the Risks of Coronavirus

June 8th 2020

How kidney cancer affects the risks of coronavirus.

Kidney Cancer Association Addresses Changes Amid Coronavirus

June 8th 2020

A message from the KCA’s CEO and President about COVID-19.

Looking at The World With a New Lens

June 6th 2020

Kidney cancer changed how Tracie saw her world.

Riding For Kidney Cancer

June 6th 2020

On his motorcycle, Stewy rides for kidney cancer.

Getting to Ring the Bell

June 6th 2020

A clinical trial and a positive attitude helped Bill Brown ring the bell.

Finding Your Own Answers to Kidney Cancer

June 6th 2020

Dawne Gee worked hard to get answers about her kidney cancer.

Keytruda-Inlyta Combination Continues to Show Superior Survival Outcomes in Advanced Renal Cell Carcinoma

June 5th 2020

“These results continue to support pembrolizumab (Keytruda) plus axitinib (Inlyta) as a standard of care for patients with previously untreated advanced RCC,” said lead study author Dr. Elizabeth R. Plimack.

MK-6482 Shows Promise in von Hippel-Lindau Disease-Associated Renal Cell Carcinoma

May 30th 2020

The HIF-2a Inhibitor induced clinical responses among patients with von Hippel-Lindau disease–associated kidney cancer, according to results presented at the 2020 ASCO Virtual Scientific Program.

Fotivda Improves Survival in Relapsed, Refractory Metastatic Renal Cell Carcinoma

May 29th 2020

When compared with Nexavar, Fotivda showed improved progression-free survival, and a more manageable safety profile for patients with relapsed or refractory metastatic renal cell carcinoma.

Approval of Keytruda Every Six Weeks a 'Welcome Change' for Patients With Cancer

May 21st 2020

“Those who are doing well and are stable in terms of safety and tolerability can come into the office less often,” Dr. David R. Spigel, said. “(This is) a big win.”

Tolerability of Fotivda Is Key in Treating Relapsed, Refractory Renal Cell Carcinoma

May 20th 2020

Dr. Brian Rini discussed the benefits of treating patients with relapsed or refractory renal cell carcinoma with the vascular endothelial growth factor tyrosine kinase inhibitor.

Opdivo-Yervoy Combination Continues to Show Superior Long-Term Outcomes in Renal Cell Carcinoma

May 11th 2020

Further follow up of the CheckMate-214 trial continues to show the superior long-term outcomes of Opdivo and Yervoy in treatment of patients with advanced renal cell carcinoma.

Novel Combination Improves Survival in Untreated Advanced Renal Cell Carcinoma

May 8th 2020

Patients with advanced renal cell carcinoma may soon have a new option in the novel combination of Opdivo (nivolumab) and Cabometyx (cabozantinib).

CURE Community Vlog: Staying Healthy During the COVID-19 Pandemic

April 29th 2020

“I’m not going to give up on that just because of this pandemic. Health is most important, as it should be for us cancer survivors.”

FDA Approves Every Six-Week Dose of Keytruda Across All Indicated Cancer Types

April 29th 2020

Keytruda, an immunotherapy that treats a variety of adult cancers, can now be given at a higher dose that requires fewer visits to clinics for infusions to support social distancing during the COVID-19 pandemic.

CURE Community Vlog: Taking Control Over a Cancer Diagnosis

April 21st 2020

“I thought, you know what I have control right now: if I'm going to laugh, if I'm going to enjoy my family, or if I'm going to hide in a corner and cry all day. I'm not going to do that. I'm not going to let cancer do that to me.”

Best Approaches for Patients with Metastatic Renal Cell Carcinoma

March 26th 2020

Once a patient progresses following initial treatment for kidney cancer, one expert says TKIs are the next step in therapy.

Combination Immunotherapy Use in Metastatic Kidney Cancer

March 24th 2020

Different combinations of immunotherapy with chemotherapy are helping patients with renal cell carcinoma live longer.